Retrospective study shows benefits of Lantus vs detemir in T2D - Sanofi

Sanofi US announced results from a real world outcome retrospective study of 13,942 Type 2 Diabetes (T2D) patients that show switching from Lantus (insulin glargine [rDNA origin] injection) to insulin detemir demonstrated higher average blood sugar levels (A1C) and lower A1C reduction over a span of 12 months compared to maintaining patients on Lantus. Alternatively, switching patients from insulin detemir to Lantus resulted in a significantly lower A1C compared to maintaining patients on insulin detemir. Cohort 1 was switched to insulin detemir (DET-S) from insulin glargine or continued on insulin glargine (GLA-C) and Cohort 2 was switched to insulin glargine (GLA-S) from insulin detemir or continued on insulin detemir (DET-S).

At one year, in Cohort 1 vs GLA-C patients, DET-S patients were significantly less persistent with treatment (52.5% vs 61.4%), had a significantly higher A1C (8.5% vs. 8.2%), experienced significantly less A1C reduction (-0.24% vs. -0.46%) and a significantly lower proportion of patients achieved A1C. At one year follow up, in Cohort 2, compared with DET-C patients, GLA-S patients had a significantly lower A1C (GLA-S: 8.1% vs. DET-C: 8.3%) and a similar A1C reduction (GLA-S: -0.6% vs. DET-C: -0.5%); the proportions of patients achieving A1C less than 7% (GLA-S: 25.1% vs. DET-C: 23.6%), A1C less than 8% (GLA-S: 54.8% vs. DET-C: 51.3%). Hypoglycemia rates were similar between groups; GLA-S patients had significantly greater weight gain than DET-C. The study findings were presented at the 74th Scientific Sessions of the American Diabetes Association.